Overview

A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)

Status:
Terminated

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

The major purpose of this study is to examine the anti-tumor activity of the CDX-1307 vaccine regimen when it is given before and after bladder cancer surgery. The study will also provide information about the safety of the vaccine regimen when given in combination with chemotherapy, and how it affects the immune systems.

Phase:

Phase 2

Details

Lead Sponsor:

Celldex Therapeutics

Treatments:

Vaccines